• +1-646-491-9876
    • +91-20-67278686

    Search

    Placenta Growth Factor-Pipeline Review H2 2017

    Placenta Growth Factor-Pipeline Review H2 2017

    • Report Code ID: RW00011060481
    • Category Life Sciences
    • No. of Pages 67
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Pipeline Review, H2 2017

    Summary

    According to the recently published report 'Placenta Growth Factor-Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

    The report 'Placenta Growth Factor-Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
    -The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Overview 6
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Therapeutics Development 7
    Products under Development by Stage of Development 7
    Products under Development by Therapy Area 8
    Products under Development by Indication 9
    Products under Development by Companies 10
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Therapeutics Assessment 13
    Assessment by Mechanism of Action 13
    Assessment by Route of Administration 14
    Assessment by Molecule Type 16
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Companies Involved in Therapeutics Development 18
    Alteogen Inc 18
    Chengdu Kanghong Pharmaceuticals Group Co Ltd 18
    Formycon AG 18
    Lupin Ltd 19
    Regeneron Pharmaceuticals Inc 20
    ThromboGenics NV 20
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Drug Profiles 22
    (aflibercept + nesvacumab)-Drug Profile 22
    Product Description 22
    Mechanism Of Action 22
    R&D Progress 22
    aflibercept-Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    aflibercept biosimilar-Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    aflibercept biosimilar-Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    aflibercept biosimilar-Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    aflibercept SR-Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    conbercept-Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    SL-186-Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    SL-188-Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    THR-317-Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    ziv-aflibercept-Drug Profile 47
    Product Description 47
    Mechanism Of Action 47
    R&D Progress 47
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Dormant Products 52
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Discontinued Products 53
    Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)-Product Development Milestones 54
    Featured News & Press Releases 54
    Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54
    May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55
    May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56
    Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57
    Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58
    Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58
    Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59
    May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60
    May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61
    Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62
    Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62
    Feb 29, 2016: Formycon discloses details on second pipeline product-FYB203 is a biosimilar for Eylea (aflibercept) 63
    Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64
    Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64
    Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65
    Appendix 66
    Methodology 66
    Coverage 66
    Secondary Research 66
    Primary Research 66
    Expert Panel Validation 66
    Contact Us 66
    Disclaimer 67

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Indication, H2 2017 9
    Number of Products under Development by Companies, H2 2017 10
    Products under Development by Companies, H2 2017 11
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
    Number of Products by Stage and Mechanism of Actions, H2 2017 13
    Number of Products by Stage and Route of Administration, H2 2017 15
    Number of Products by Stage and Molecule Type, H2 2017 17
    Pipeline by Alteogen Inc, H2 2017 18
    Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18
    Pipeline by Formycon AG, H2 2017 19
    Pipeline by Lupin Ltd, H2 2017 19
    Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20
    Pipeline by ThromboGenics NV, H2 2017 21
    Dormant Projects, H2 2017 52
    Discontinued Products, H2 2017 53

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Top 10 Indications, H2 2017 9
    Number of Products by Stage and Mechanism of Actions, H2 2017 13
    Number of Products by Routes of Administration, H2 2017 14
    Number of Products by Stage and Routes of Administration, H2 2017 14
    Number of Products by Molecule Types, H2 2017 16
    Number of Products by Stage and Molecule Types, H2 2017 16
    Alteogen Inc
    Chengdu Kanghong Pharmaceuticals Group Co Ltd
    Formycon AG
    Lupin Ltd
    Regeneron Pharmaceuticals Inc
    ThromboGenics NV

    Request for Sample

    Report Url https://www.reportsweb.com//placenta-growth-factor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//placenta-growth-factor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//placenta-growth-factor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments